Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not yet recruitingRare disease

Study on Pegfilgrastim for Patients with Severe Chronic Neutropenia

Registered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a condition known as severe chronic neutropenia (SCN). This is a disorder where the body has a lower than normal number of a type of white blood cell called neutrophils, which are important for fighting off infections. The treatment being tested in this study is a medication called pegfilgrastim, which is marketed under the name Neulasta. Pegfilgrastim is a type of medicine known as a colony-stimulating factor, which helps the body produce more neutrophils.

The purpose of the study is to evaluate how effective pegfilgrastim is in maintaining a healthy level of neutrophils in patients with severe chronic neutropenia who are already receiving daily treatment with another medication called G-CSF and anti-infective therapy. The study will observe patients over a period of time to see if pegfilgrastim can help keep their neutrophil levels above a certain threshold, which is important for reducing the risk of infections.

Participants in the study will receive pegfilgrastim as a solution for injection, administered under the skin. The study will monitor the number of infections, the use of antibiotics, and any hospitalizations that occur during the study period. This information will help determine the effectiveness of pegfilgrastim in managing severe chronic neutropenia. The study is expected to continue until 2030, providing valuable insights into the long-term benefits of this treatment.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment

    The trial begins with an initial assessment to confirm eligibility. This involves verifying that the absolute neutrophil count is less than 500/mmc based on three consecutive tests conducted at least one week apart over a minimum three-month period.

    Eligibility is confirmed for patients already receiving daily treatment with G-CSF and anti-infective therapy.

  2. Step 2

    Medication administration

    The medication used in this trial is Neulasta, which contains the active substance pegfilgrastim. It is administered as a solution for injection.

    The injection is given subcutaneously, meaning it is injected under the skin.

    The dosage is 6 mg per injection. The frequency and duration of administration are determined by the study protocol and the patient's response.

  3. Step 3

    Monitoring and evaluation

    Throughout the trial, the absolute neutrophil count is monitored to ensure it remains above 1000/mmc.

    The primary endpoint is the median of the absolute neutrophil count from the second to the sixth month of the study.

    Secondary endpoints include the number, type, and duration of infections, the number of antibiotic courses, and the number of hospitalizations during the same period.

  4. Step 4

    Follow-up

    Regular follow-up appointments are scheduled to assess the patient's health and response to the treatment.

    These appointments include reviewing any side effects, infections, or hospitalizations that may occur during the trial.

  5. Step 5

    Completion

    The trial is estimated to end on September 28, 2030.

    Upon completion, the data collected will be analyzed to evaluate the efficacy of pegfilgrastim in maintaining the desired neutrophil levels and reducing infection-related complications.

Who can join the trial?

5 criteria

  • Patients of any age can participate.
  • Both males and females are eligible.
  • Patients must have either congenital (present from birth) or acquired (developed later) chronic neutropenia.
  • Chronic neutropenia is defined as having an absolute neutrophil count (a type of white blood cell) of less than 500 per cubic millimeter, based on three tests done at least one week apart over a minimum of three months.
  • Patients must already be receiving treatment with G-CSF (a medication given daily to help increase white blood cells).

Who cannot join the trial?

5 criteria

  • Patients who are not already being treated with G-CSF, which is a medication used to help the body make more white blood cells.
  • Patients who are not receiving anti-infective therapy, which is treatment to prevent or fight infections.
  • Patients who do not have severe chronic neutropenia, a condition where the body has a very low number of a type of white blood cell called neutrophils.
  • Patients who are outside the specified age range for the study.
  • Patients who are not part of the specified clinical trial groups.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Pegfilgrastim

    is a medication used in this trial to help increase the number of white blood cells, specifically neutrophils, in patients with severe chronic neutropenia. It is designed to maintain neutrophil levels above a certain threshold to help reduce the risk of infections. This medication is a long-acting form of a protein that stimulates the bone marrow to produce more neutrophils.

  • G-CSF

    (Granulocyte Colony-Stimulating Factor) is another medication used in the trial. It is administered daily to help increase the production of neutrophils in the bone marrow. This medication is crucial for patients with severe chronic neutropenia to help prevent infections by maintaining adequate levels of neutrophils in the blood.

  • Anti-infective therapy

    is also part of the treatment regimen in this trial. This therapy involves the use of medications that help prevent or treat infections. Patients with severe chronic neutropenia are at a higher risk of infections due to low neutrophil counts, so anti-infective therapy is important to protect them from potential infections.

What is already known about the treatment

Pegfilgrastim – Pegfilgrastim is administered via subcutaneous injection and is currently used in medical practice to treat severe chronic neutropenia (SCN). It is well-documented in medical literature as an effective treatment for this condition. The main therapeutic indication for pegfilgrastim is to help maintain adequate levels of neutrophils, a type of white blood cell, in patients with SCN. At the molecular level, pegfilgrastim works by stimulating the bone marrow to produce more neutrophils, enhancing the body's ability to fight infections. It is classified pharmacologically as a granulocyte colony-stimulating factor (G-CSF).

Investigated diseases

Severe Chronic Neutropenia – Severe chronic neutropenia is a condition characterized by an abnormally low number of neutrophils, a type of white blood cell essential for fighting off infections. This disease can be congenital, cyclic, or idiopathic, meaning its cause is unknown. Individuals with this condition often experience frequent infections due to their compromised immune system. The progression of the disease involves persistent low neutrophil counts, which can lead to recurrent bacterial infections, particularly affecting the skin, respiratory tract, and other areas. Over time, the condition may cause complications due to repeated infections and inflammation. Management typically focuses on maintaining neutrophil levels to reduce infection risk.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-519009-36-01Protocol codeCDF 711Estimated enrolment20 patients

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).